|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Mayo Clinic Engineers & Doctors Wallsten Medical Group |
| Information provided by: | Mayo Clinic |
| ClinicalTrials.gov Identifier: | NCT00166361 |
Purpose
The purpose of this study is to evaluate the safety and efficacy of the Memokath 051 ureteral stent as a long-term temporary and minimally invasive means of providing ureteral drainage in the setting of malignant extrinsic ureteral obstruction secondary to inoperable abdominal or pelvic malignancies. Up to 15 adults who have extrinsic ureteral obstruction secondary to an inoperable abdominal or pelvic malignancy and need ureteral stent drainage will undergo outpatient placement of the ureteral stent. Ongoing monitoring will continue for as long as the stent is in place.
| Condition | Intervention |
|
Ureteral Obstruction |
Device: Memokath 051 Ureteral Stent |
| MedlinePlus related topics: | Cancer |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment |
| Official Title: | Long-Term Temporary Drainage of Malignant Extrinsic Ureteral Obstruction Secondary to Inoperable Pelvic or Abdominal Malignancies Using the Memokath 051 Ureteral Stent |
| Estimated Enrollment: | 25 |
| Study Start Date: | March 2004 |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Contacts and Locations| United States, Minnesota | |||||
| Mayo Clinic | Recruiting | ||||
| Rochester, Minnesota, United States, 55905 | |||||
| Contact: Karla A Knoke-Sandoe 507-284-3369 | |||||
| Principal Investigator: Lance A Mynderse, M.D. | |||||
| Mayo Clinic |
| Engineers & Doctors Wallsten Medical Group |
| Principal Investigator: | Lance A Mynderse, M.D. | Mayo Clinic |
More Information
| Study ID Numbers: | 255-03 |
| First Received: | September 12, 2005 |
| Last Updated: | January 26, 2006 |
| ClinicalTrials.gov Identifier: | NCT00166361 |
| Health Authority: | United States: Food and Drug Administration |
|